UNSPSC 51313425: Chlorpheniramine tannate

This classification denotes a histamine-1 receptor antagonist with the molecular formula C76H52O46.C16H19CLN2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 72JT935YTT. European Medicines Agency schedules chlorphenamine tannate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01244MIG. Most nations, for tariff and trade purposes, schedule chlorpheniramine tannate under HS 29333910. SMILES:. As of Q4 2014, CHLORPHENIRAMINE TANNATE remains US FDA's Preferred Term for this commodity..

Chlorpheniramine tannate bears US NLM identifiers UMLS ID C0724552 and NCI Concept Code C97692.

UNSPSC 51313425 Chlorpheniramine tannate is a Commodity code that in practice captures state and local procurement of pharmaceuticals and over-the-counter products, though recent opportunities show minimal direct activity under this specific drug SKU and instead reflect broader pharmaceutical procurement patterns across generic multi-source products and specialized pharmacy initiatives. State and local governments buy pharmaceuticals through cooperative purchasing alliances, county health departments, and state health agencies that aggregate demand across multiple jurisdictions and facility types. Issuing bodies include county public health departments (such as Seminole County, Florida), state health and human services agencies (such as the Texas Health and Human Services Commission), and multistate cooperative purchasing organizations (such as the Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). Procurement typically requires vendors to hold current Good Manufacturing Practices certification, maintain Drug Supply Chain Security Act compliance, work through authorized pharmaceutical wholesalers, and meet insurance and E-Verify requirements.

Recent activity centers on Florida, Texas, and Minnesota. Seminole County, Florida released IFB 60459723LAS (posted June 30, 2026, response due July 26, 2023) to procure 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building; the Texas Health and Human Services Commission issued RFI HHS0017013 (posted April 3, 2026) to gather vendor capacity information on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements; and MMCAP, administered by the Minnesota Department of Administration, released an RFP (posted January 20, 2026, questions due February 18, 2026, proposals due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, with pricing weighted at 75 percent and mandatory use of three authorized wholesalers. The MMCAP opportunity specifies a two-year contract term with optional extensions and a 3 percent administrative fee on all purchases, while the Seminole County procurement includes a two-year initial term with a one-year renewal option.